CD4: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It's the GeneMedi's summary page for Target/Biomarker Introduction of CD4. The page also collects GeneMedi's different modalities and formats products for CD4 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the CD4 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

This gene encodes the CD4 membrane glycoprotein of T lymphocytes. The CD4 antigen acts as a coreceptor with the T-cell receptor on the T lymphocyte to recognize antigens displayed by an antigen presenting cell in the context of class II MHC molecules. The CD4 antigen is also a primary receptor for entry of the human immunodeficiency virus through interactions with the HIV Env gp120 subunit. This gene is expressed not only in T lymphocytes, but also in B cells, macrophages, granulocytes, as well as in various regions of the brain. The protein functions to initiate or augment the early phase of T-cell activation, and may function as an important mediator of indirect neuronal damage in infectious and immune-mediated diseases of the central nervous system. Multiple alternatively spliced transcript variants encoding different isoforms have been identified in this gene. [provided by RefSeq, May 2020]

Pre-made CD4-specific INN-index biosimilar (antibody&conjugates)-Zanolimumab, priliximab, clenoliximab, Ibalizumab, keliximab, Tregalizumab, cedelizumab

Anti-CD4 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cat No.	Products Name (INN Index)	INN Name	Previous Name	Target	Format	Order
GMP-Bios-ab-640	Pre-Made Zanolimumab biosimilar, Whole mAb, Anti-CD4 Antibody: Anti-IMD79/OKT4D therapeutic antibody	Zanolimumab		CD4	Whole mAb
GMP-Bios-INN-965	Pre-Made Priliximab Biosimilar, Whole Mab, Anti-Cd4 Antibody: Anti-IMD79/OKT4D therapeutic antibody	priliximab		CD4	Whole  mAb
GMP-Bios-INN-782	Pre-Made Clenoliximab Biosimilar, Whole Mab, Anti-Cd4 Antibody: Anti-IMD79/OKT4D therapeutic antibody	clenoliximab		CD4	Whole  mAb
GMP-Bios-ab-257	Pre-Made Ibalizumab biosimilar, Whole mAb, Anti-CD4 Antibody: Anti-IMD79/OKT4D therapeutic antibody	Ibalizumab		CD4	Whole mAb
GMP-Bios-INN-881	Pre-Made Keliximab Biosimilar, Whole Mab, Anti-Cd4 Antibody: Anti-IMD79/OKT4D therapeutic antibody	keliximab		CD4	Whole  mAb
GMP-Bios-ab-594	Pre-Made Tregalizumab biosimilar, Whole mAb, Anti-CD4 Antibody: Anti-IMD79/OKT4D therapeutic antibody	Tregalizumab		CD4	Whole mAb
GMP-Bios-INN-773	Pre-Made Cedelizumab Biosimilar, Whole Mab, Anti-Cd4 Antibody: Anti-IMD79/OKT4D therapeutic antibody	cedelizumab		CD4	Whole  mAb

Pre-made anti-CD4 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-CD4 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CD4 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cat No.	Antibody Name	Format	Classified by tag	Order
GM-Tg-hg-T10191-Ab	Anti-CD4 monoclonal antibody	mab	Biofunctional antibody, Therapeutics Target antibody